Navigation Links
Synthetech Announces New Director of Manufacturing
Date:9/30/2008

ALBANY, Ore., Sept. 30 /PRNewswire-FirstCall/ -- Synthetech, Inc. (OTC Bulletin Board: NZYM) announced today the appointment of Dr. Frederic Farkas as Director of Manufacturing effective on October 1, 2008. Since May 2008, Dr. Farkas has provided consulting services to Synthetech. Dr. Farkas has over 13 years' experience with amino acid derivatives, peptides and API manufacturing from previous positions in manufacturing and supply chain management at Bachem Corporation, Novartis AG and Senn Chemicals Company, where he most recently served as Director of Manufacturing. Dr. Farkas earned a Bachelor of Science degree in Chemistry and a Doctor of Philosophy, Organic Chemistry, both from University Basel in Switzerland.

"We are very pleased to have Frederic join Synthetech and contribute his production skills and knowledge," stated Dr. Gregory R. Hahn, President and CEO. "Frederic brings extensive manufacturing management experience from both the pharmaceutical and fine chemical industries."

"I am pleased with the opportunity to improve production performance and continue the turnaround efforts at Synthetech," said Dr. Farkas. "Synthetech has developed an excellent reputation in unnatural amino acids, peptide chemistry and multi-step chiral organic synthesis. I am eager to build on Synthetech's strengths and look forward to meeting the challenge of improving manufacturing efficiencies and costs. I also look forward to working with the Synthetech team to meet both the short- and long-term challenges at Synthetech."

About Synthetech

Synthetech, Inc. is a fine chemicals company specializing in organic synthesis, biocatalysis and chiral technologies. Synthetech develops and manufactures amino acid derivatives, specialty amino acids, peptide fragments, proprietary custom chiral intermediates and specialty resins, primarily for the pharmaceutical industry. Synthetech's products support the development and manufacture of therapeutic peptides and peptidomimetic small molecule drugs at every stage of a customer's clinical development pipeline, and are used as ingredients in drugs for the treatment of AIDS, cancer, cardiovascular and other diseases.

MORE INFORMATION: Web site: http://www.synthetech.com

E-mail: investor@synthetech.com

CONTACT: Gary Weber, CFO

PO Box 646

Albany, Oregon 97321

541 967-6575


'/>"/>
SOURCE Synthetech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetech Announces Fiscal 2008 Results
2. Synthetech Earns National Recognition for Performance Improvement Program
3. Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
4. Biotel Announces Record Revenues and Earnings for Fiscal 2008
5. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
6. Helix BioPharma Announces $11.4 Million Private Placement
7. ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver
8. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
9. Nomad Bioscience Announces Broad License Agreement
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
11. Update: HYSTA Announces Dr. Qi Lu to Continue on as President of HYSTA, USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... 12, 2017 , ... Huffman Engineering, Inc. , a leader in control ... the company’s Lincoln office as a chemical engineer. In his new role, Beck ... in the life science manufacturing and water/wastewater industries. , Prior to joining Huffman Engineering, ...
(Date:1/12/2017)... India , January 12, 2017 A new report published ... End Users - Global Opportunity Analysis and Industry Forecast, 2014-2022," projects that the global ... in 2015, growing at a CAGR of 15.07% during the forecast period. ... ... Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... specialists with accurate and reliable preimplantation genetic screening (PGS). , “Our genetics and ... results,” says Ovation Fertility Genetics Scientific Director Amy Jones, M.S., ELD (ABB) ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... and costing healthcare systems more than $23.7 billion, healthcare systems are looking ... , Among the most common sepsis-causing pathogens are bacteria and the yeast pathogen ...
Breaking Biology Technology:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL anunció ... acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar a ... con múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el ... de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos ...
(Date:12/15/2016)... , December 15, 2016 Arvato ... an agreement with NuData Security, an award-winning international ... will enable clients to focus on good customer experience, balancing ... regulation. ... In order to provide a one-stop fraud prevention suite, Arvato ...
(Date:12/15/2016)... 15, 2016  There is much more to innovative ... the engine. Continental will demonstrate the intelligence of today,s ... . Through the combination of the keyless entry ... biometric elements, the international technology company is opening up ... authentication. "The integration of biometric elements brings ...
Breaking Biology News(10 mins):